Home › Encyclopedia › Gonadorelin: Uses, Evidence, and Clinical Data
Approved

Gonadorelin: Uses, Evidence, and Clinical Data

Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.

Molecular formulaC55H75N17O13
Molecular weight1182.3 g/mol
Registered trials1324
PubChem CID638793

Anyone researching gonadorelin usually wants to know what it is and how much clinical study backs it up. This overview summarizes the available identity and trial data without going into label specifics that were not provided.

Key takeaways

  • Gonadorelin is a peptide compound with the molecular formula C55H75N17O13 and a molecular weight of about 1182.3.
  • More than 1,300 clinical trials are registered that involve gonadorelin or related study arms.
  • Sample trials span oncology contexts, including breast and prostate cancer research.
  • No FAERS adverse event report data or label text was available for this summary.

What gonadorelin is

Gonadorelin is a synthetic peptide identified by PubChem CID 638793. Its structure is a chain of amino acid residues with a molecular formula of C55H75N17O13 and a molecular weight near 1182.3. Beyond this chemical identity, no label mechanism or drug class text was provided for this summary.

What the evidence shows

Clinical trial registries list 1,324 trials associated with gonadorelin. Among the sampled studies, one completed trial examined Zoladex plus tamoxifen in breast cancer, though it was not assigned a phase designation. Another trial, a Phase 1 study of DWJ108J administered subcutaneously in patients with prostate cancer, has an unknown status. A separate Phase 2 study evaluated dasatinib for androgen-deprived progressive prostate cancer and has completed.

Reported side effects

No FAERS adverse event report data was available for gonadorelin in this dataset, so no side effect summary can be provided here.

FAQ

What is gonadorelin?
Gonadorelin is a synthetic peptide compound with the molecular formula C55H75N17O13 and a molecular weight of about 1182.3. It is identified in chemical databases under PubChem CID 638793. No label mechanism or drug class information was available in this summary.
How many clinical trials have studied gonadorelin?
Registries list 1,324 trials associated with gonadorelin or related study arms. These span multiple research contexts, including oncology studies such as breast and prostate cancer trials.
What do the sample trials show about gonadorelin research?
Sample trials include a completed study of Zoladex plus tamoxifen in breast cancer, a Phase 1 pharmacokinetics and safety study in prostate cancer patients with unknown status, and a completed Phase 2 study of dasatinib in progressive prostate cancer. These examples illustrate the range of trial designs but do not establish efficacy on their own.
Are there known side effects of gonadorelin?
No FAERS adverse event report data was available for gonadorelin in this summary, so a side effect pattern cannot be described here. Readers should consult official prescribing information or a healthcare provider for safety details.
Is gonadorelin FDA approved?
This summary reflects an approved regulatory status, though specific label indications were not available in the data reviewed. Approved brand names and indications could not be summarized without label text.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem CID 638793 ClinicalTrials.gov aggregate count ClinicalTrials.gov trial records (NCT00827307, NCT03029533, NCT00385580)

Updated 2026-08-10